Company to view next
Generic selectors
Exact matches only
Search in title
Search in content

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company’s lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

11

Address:

Aprea Therapeutics, Inc. 535 Boylston Street Boston MA 02116 United States

Website:

Home

Phone:

617-463-9385

Leave a comment

Your email address will not be published. Required fields are marked *